Progression on BTK Inhibitors: Treatment Options and Considerations

EP: 1.Recent Guideline Updates in the Frontline Management of CLL

EP: 2.Tailoring Treatment Approaches for Fit vs Unfit CLL Patients

EP: 3.Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated CLL Patients

EP: 4.Time-Limited Therapy with Venetoclax-Obinutuzumab: Rationale and Data

EP: 5.Clinical Insights and Real-World Evidence

EP: 6.Doublet Therapy With Venetoclax-Ibrutinib: Data and Guidelines

EP: 7.Comparing Venetoclax-Ibrutinib, Venetoclax-Obinutuzumab, and BTKi Options

EP: 8.Managing CLL with TP53 Mutation or del(17p): Guidelines and Strategies

EP: 9.Exploring Novel BCL2i and BTKi Combinations in Frontline CLL Therapy

EP: 10.Relapse After Venetoclax-Based Therapy: Early vs Late Management

Now Viewing

EP: 11.Progression on BTK Inhibitors: Treatment Options and Considerations

EP: 12.Emerging Agents and Future Strategies in Relapsed/Refractory CLL

EP: 13.Reflections and Future Directions in CLL Management

Video content above is prompted by the following:

• Briefly comment on the role of combination venetoclax-ibrutinib in this setting and available supporting data (high level).
  • CLARITY – Hillmen P. et al. J Clin Oncol. 2019;37(30):2722-2729
  • VISION – Kater AP, et al. Lancet Oncol. 2022;23(6):818-828
• What is the potential role for venetoclax in combination with 2^nd generation BTKis in this setting? (Ahn IE, et al. ASH 2024. Abs 1874)
• Briefly review recent ESMO guideline updates for managing patients with R/R CLL who experience disease progression on a BTKi. (ESMO CLL Guideline Update 2024)
• How does your treatment approach differ for patients who progress on first-line BTK inhibitor therapy versus those who are intolerant to it?
• When would you opt for an alternative BTKi vs changing to a venetoclax-based regimen?